Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Shots:

  • (NCT01243424) study results involve assessing of Tradjenta (5mg, qd) vs glimepiride in patients with type2 diabetes across 43 countries for 6+years
  • The CAROLINA study resulted in meeting its 1EPs i.e, occurrence of 3P-MACE (11.8% vs 12.0%), 3P-MACE + 4P-MACE (13.2% vs 13.3%), 2EPs (16.0% vs 10.2%), 77% reduction in risk of hypoglycemia; no new safety signals is observed
  • Tradjenta is dipeptidyl peptidase-4 (DPP-4) inhibitor indicated with diet and exercise to reduce blood sugar in adults with type 2 diabetes

Click here to read full press release/ article | Ref: Eli Lilly | Image: Spacewell Interiors